Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis

Interactive Cardiovascular and Thoracic Surgery

Volumn 14, Issue 5, 2012, Pages 565-569

  Toyooka, Shinichi ^a   Kiura, Katsuyuki ^a   Takemoto, Mitsuhiro ^b   Oto, Takahiro ^a   Takigawa, Nagio ^a   Fujiwara, Toshiyoshi ^a   Miyoshi, Shinichiro ^a   Date, Hiroshi ^c  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b HIMEJI RED CROSS HOSPITAL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Induction chemoradiotherapy; N2; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; GEMCITABINE; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BILOBECTOMY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; ESOPHAGITIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER TOXICITY; LOBAR PNEUMONIA; LONG TERM SURVIVAL; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG TOXICITY; LYMPH NODE METASTASIS; MALE; MEDIASTINAL LYMPH NODE METASTASIS; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SLEEVE LOBECTOMY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PNEUMONECTOMY; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863424070     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivs028     Document Type: Article

References (14)

1. Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S et al.: Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006;1:810-5.
2. Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
3. van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F et al.: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-50.
4. Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N et al. Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003;89:795-802.
5. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010;28:3299-306.
6. Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 2004;90:979-84.
7. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
9. Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007;133:1179-85.
10. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
11. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT III, Weick JK et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-92.
12. Jaklitsch MT, Herndon JE II, DeCamp MM Jr, Richards WG, Kumar P, Krasna MJ et al. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. J Surg Oncol 2006;94:599-606.
13. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-31.
14. Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 2009;10:785-93.